Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer.

X
Trial Profile

A Phase II Study of RAD001 in Patients With Recurrent Endometrial Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jan 2015 The primary endpoint has been changed from RAD001 can shrink or slow the growth of tumors to objective response plus stable disease rate along with change in assessment duration from 4 years to 8 weeks as per ClinicalTrials.gov record.
    • 07 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top